Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based Jupiter Biosciences is in talks to buy privately held Swiss pharma company SynphaBase for $10m in an effort to boost its research capabilities and front-end sale of its products internationally.
Subscribe to our email newsletter
If successful, the deal will mark Jupiter’s second acquisition in Switzerland after it acquired Merck Biosciences’ manufacturing facilities in 2008.
SynphaBase, backed by Novartis Venture Fund, has annual revenues of $7m and employs 25 people.
Jupiter, which plans to bring the management of the two firms under one roof, may complete the deal next month, according to a source from the company.
Jupiter plans to ship the raw material to the Swiss company, which will process and supply organic and chiral API – the basic raw materials used in drugs – to both generic drugmakers and innovator companies in the US, Europe and Japan.
SynphaBase provides contract research and development services specialising in organic and medicinal chemistry, while Jupiter Biosciences specialises in synthesis of peptides, a type of protein.